80 results
S-3ASR
IMNM
Immunome Inc
3 Apr 24
Automatic shelf registration
4:40pm
was not previously appreciated. In January 2023, we announced an agreement with AbbVie under which AbbVie paid us $30 million upfront for access to up to 10 targets … requirements in future filings. As a result, our stockholders may not have access to certain information that they may deem important
S-3ASR
IMNM
Immunome Inc
3 Apr 24
Automatic shelf registration
4:36pm
for access to up to 10 targets identified through our discovery platform.
On October 2, 2023, we completed a merger with MorphImmune Inc … not have access to certain information that they may deem important and the information that we provide to our stockholders may be different than
8-K
EX-10.1
ncamoya6sw83
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
133fap ab
14 Feb 24
Other Events
4:11pm
424B5
qzv46
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
qkwm943kp24su jddmps
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.1
chm127 jqr3g06
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
yy62006j
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
9a76752th hh
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
EX-4.3
3crkgt
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
fvk5sba72uqp
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-10.1
k2ylrl82tf7l2vb
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-99.1
ivpwpa
11 Jan 24
Regulation FD Disclosure
5:27pm
8-K
EX-99.1
a7m99xl7x 3nntz7394
15 Nov 23
Regulation FD Disclosure
6:03am